Biliary Tract Cancer (BTC) Patient Pool Analysis, Market Size and Market Forecast APAC - 2036

Biliary Tract Cancer (BTC) Insights and Trends

• Biliary tract cancer (BTC) is a group of rare but highly aggressive malignancies arising from the epithelial lining of the biliary system, including Gall Bladder Cancer (GBC), intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma (eCCA), and cancer of the ampulla of Vater. Although BTC is associated with disproportionately high mortality due to late-stage diagnosis and limited curative treatment options.
• Despite accounting for 59.05% of the global population, Asia represents a disproportionately high 71.9% share of the global incidence of biliary tract cancers.
• In Australia, Cholangiocarcinoma is slightly more prevalent in males and is predominantly diagnosed in patients aged over 70 years.
• In China, gallbladder cancer shows a significantly higher incidence in females, while intrahepatic and extrahepatic cholangiocarcinoma are more commonly observed in males.
• Therapeutic management of BTC is driven by disease stage and anatomical subtype. Early-stage BTC is potentially curable with surgical resection; however, eligibility is limited due to late diagnosis, and high post-surgical recurrence necessitates adjuvant systemic therapy, reflecting the limited durability of surgery alone. In unresectable or metastatic disease, first-line chemotherapy remains the standard of care but offers only modest and short-lived benefit, with rapid disease progression leading to high attrition and limited access to subsequent lines of therapy.
• Surgical resection remains the mainstay curative option for localized BTC and cholangiocarcinoma, with resectability strongly determining long-term outcomes. Patients with early-stage disease who are surgical candidates achieve significantly better prognoses than those with advanced disease.
• Platinum-based combination chemotherapy has historically served as the backbone of systemic therapy in advanced or unresectable disease, forming a foundational standard of care that many subsequent regimens build upon.
• The BTC treatment landscape in the APAC region is rapidly advancing with the approval of pemigatinib (PEMAZYRE), zanidatamab (ZIIHERA), pembrolizumab (KEYTRUDA), durvalumab (IMFINZI), and others, reflecting increasing adoption of biomarker-driven and immunotherapy-based treatment approaches for FGFR2-, HER2-, and PD-1/PD-L1-positive BTC populations.
• The emerging BTC pipeline is increasingly focused on next-generation targeted therapies, bispecific antibodies, and combination immunotherapies, with candidates such as rilvegostomig, tucatinib-based regimens BOLD-100, and others aiming to address unmet needs in molecularly selected and chemotherapy-refractory BTC patients.

DelveInsight's 'Biliary Tract Cancer (BTC) - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the Biliary Tract Cancer (BTC), historical and forecasted epidemiology, as well as the BTC market trends in the APAC region (India, China, South Korea, Taiwan, and Australia)

The Biliary Tract Cancer (BTC) market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates BTC patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in BTC and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Biliary Tract Cancer (BTC) Market

• Rising disease recognition and diagnosis

Rising disease recognition and better diagnostics are expanding the BTC market by improving early and accurate detection of biliary tract cancers. Greater use of imaging, biomarker testing, and molecular profiling is increasing the diagnosed patient pool and supporting the adoption of precision therapies.

• Shift toward precision oncology leading to integration of bispecific antibodies, ADCs, etc

The shift toward precision oncology is driving market growth through the increasing adoption of targeted therapies such as bispecific antibodies and ADCs. Rising use of biomarker-driven and personalized treatment approaches is accelerating demand for highly selective therapies with improved efficacy and safety profiles, thereby supporting market expansion.

Biliary Tract Cancer (BTC) Understanding and Treatment Algorithm

Biliary Tract Cancer (BTC) Overview and Diagnosis

BTC is a heterogeneous group of rare and aggressive malignancies arising from the epithelial lining of the biliary system, including intrahepatic and extrahepatic cholangiocarcinoma, gallbladder cancer, and ampulla of Vater cancer. These cancers are often diagnosed at advanced stages due to nonspecific symptoms and limited early detection strategies. Prognosis remains poor, particularly for advanced disease, with limited curative options outside of early surgical resection. Systemic chemotherapy has historically been the mainstay of treatment for unresectable or metastatic BTC. However, advances in molecular profiling have led to the emergence of targeted therapies and immunotherapies, improving outcomes for selected patient subgroups.

Diagnosis of BTC is often challenging due to nonspecific clinical symptoms such as jaundice, abdominal pain, weight loss, and pruritus. Initial evaluation typically includes liver function tests and tumor markers such as CA 19-9, although these lack specificity. Imaging modalities, including ultrasound, contrast-enhanced CT, and MRI/Magnetic Resonance Cholangiopancreatography (MRCP), are central to detecting tumors, defining anatomical extent, and assessing resectability. Endoscopic procedures such as Endoscopic Retrograde Cholangiopancreatography (ERCP) or Endoscopic Ultrasound (EUS) may be used for tissue sampling and biliary drainage. Histopathological confirmation is required for definitive diagnosis, and molecular testing is increasingly performed to identify actionable genetic alterations that guide targeted therapy selection.

Biliary Tract Cancer (BTC) Treatment

Treatment of BTC depends on tumor location, stage, and patient fitness. Surgical resection offers the only potential cure and is primarily feasible in early-stage disease, particularly in countries with stronger screening and hepatobiliary care infrastructure, such as Japan and South Korea, often followed by adjuvant chemotherapy to reduce recurrence risk. For unresectable or metastatic BTC, systemic chemotherapy, most commonly gemcitabine-based regimens, has been the standard of care. In selected patients, locoregional therapies such as radiotherapy or transarterial approaches may be considered for disease control or symptom palliation. Advances in molecular profiling have enabled the use of targeted therapies (e.g., FGFR and IDH1 inhibitors) and immunotherapies for biomarker-defined subgroups. Palliative care, including biliary drainage and symptom management, remains an important component of treatment for advanced disease.

Biliary Tract Cancer (BTC) Unmet Needs

The section "unmet needs of BTC" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Lack of Effective Early Detection and Diagnostic Biomarkers

2. Insufficient Understanding of Disease Heterogeneity

3. Barriers to Clinical Trial Enrollment and Novel Drug Development, and others.....

Biliary Tract Cancer (BTC) Epidemiology

Key Findings from BTC Epidemiological Analysis and Forecast

• Among BTCs, gallbladder cancer is one of the most aggressive and lethal subtypes, representing approximately 1.3% of overall global cancer incidence. India accounts for nearly 10% of the global gallbladder cancer burden.
• In China, the disease burden of gallbladder and biliary tract cancer (GBTC) is higher in males than in females, with incidence rates increasing significantly in older age groups.
• In 2025, intrahepatic cholangiocarcinoma (ICC) in South Korea demonstrated lower frequencies of IDH1 mutations and FGFR2 fusions, whereas gallbladder cancer exhibited a comparatively higher prevalence of ERBB2 (HER2) amplification.
• TP53 is the most frequently mutated gene in BTCs, followed by KRAS, ARID1A, IDH1, and PIK3CA. TP53 mutations were prevalent across both gallbladder cancer and cholangiocarcinoma, while IDH1 mutations were predominantly associated with cholangiocarcinoma.

Biliary Tract Cancer (BTC) Drug Analysis & Competitive Landscape

The BTC drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships, upcoming key catalysts for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the BTC treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the BTC market.

Approved Therapies for BTC

Zanidatamab (ZIIHERA): Zymeworks/Jazz Pharmaceuticals

Zanidatamab is a dual HER2-targeted bispecific antibody that binds extracellular domains 2 and 4 on separate HER2 receptors, promoting receptor internalization and activating multiple immune-mediated anti-tumor mechanisms, including CDC, ADCC, and ADCP, leading to tumor cell death and growth inhibition. Developed by Zymeworks and partnered with BeOne Medicines in Asia-Pacific markets, zanidatamab received conditional approval from the National Medical Products Administration (NMPA) in China in May 2025 for previously treated unresectable or metastatic HER2-positive BTC, becoming the first approved dual HER2-targeted bispecific antibody for HER2-high (IHC3+) BTC in the country.

Subsequently, in March 2026, the Ministry of Food and Drug Safety approved zanidatamab for adult patients with unresectable, locally advanced, or metastatic HER2-positive (IHC3+) BTC who had received at least one prior systemic therapy in South Korea.

Pemigatinib (PEMAZYRE): Incyte

Pemigatinib is an oral, selective FGFR1/2/3 inhibitor and orphan targeted therapy approved for previously treated, unresectable, locally advanced, or metastatic BTC/cholangiocarcinoma with FGFR2 fusion or rearrangement. The drug inhibits aberrant FGFR signaling involved in tumor growth and survival and has demonstrated durable clinical responses in patients progressing after prior systemic therapy. The drug was discovered by Incyte and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau, and Taiwan.

It received approvals across multiple Asia-Pacific markets, including Taiwan (2021), China (2022), Australia (2022), and South Korea (2023), where it was approved as a fast-track reviewed targeted therapy for locally progressive or metastatic bile duct cancer.

Biliary Tract Cancer (BTC) Pipeline Analysis

Rilvegostomig: AstraZeneca and Compugen

Rilvegostomig is a first-in-class dual-checkpoint bispecific that delivers coordinated PD-1 and TIGIT blockade on the same immune effector cell, restoring antitumor immune activity and supporting the potential for durable, long-term outcomes. The TIGIT component of rilvegostomig is derived from Compugen's fully owned COM902, which is one of only two clinical-stage Fc-reduced anti-TIGIT monoclonal antibodies currently in development. Currently, the drug is being evaluated in multiple Phase III trials in patients with BTC.

Lenvatinib mesylate (LENVIMA): Merck and Eisai

Lenvatinib is an orally administered multi-RTK inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other pathway-related RTKs (including the platelet-derived growth factor (PDGF) receptor PDGFRa; KIT; and RET) involved in tumor angiogenesis, tumor progression and modification of tumor immunity.

Currently, the drug is being evaluated in a Phase II clinical trial for treatment of patients with cholangiocarcinoma.

Biliary Tract Cancer (BTC) Key Players, Market Leaders, and Emerging Companies

• AstraZeneca
• Compugen
• Zymeworks
• Incyte
• Jazz Pharmaceuticals
• Merck
• Eisai
• Pfizer
• Bold Therapeutics, and others

Biliary Tract Cancer (BTC) Drug Updates

• As of May 2026, Compugen anticipates key efficacy data for rilvegostomig from the Phase III DESTINY-BTC01 trial in 2027.
• In December 2025, Compugen announced an agreement with AstraZeneca to monetize a portion of its future royalties from rilvegostomig. As part of this transaction, Compugen amended its exclusive license agreement with AstraZeneca, originally executed in March 2018, to strengthen its balance sheet and advance its differentiated immuno-oncology pipeline.

Drug Class Insights

Biliary Tract Cancer (BTC) Market Outlook

Curative management of BTC, including cholangiocarcinoma and gallbladder cancer, is primarily based on surgical resection, followed by adjuvant capecitabine, which has demonstrated a survival benefit in the postoperative setting. However, recurrence rates remain high, underscoring a substantial unmet need for more effective adjuvant strategies. The majority of patients present with advanced or unresectable disease, where systemic chemotherapy remains the backbone of treatment. In this setting, cisplatin plus gemcitabine constitutes the standard first-line regimen, while second-line options typically include 5-fluorouracil-based combinations, such as FOLFOX or irinotecan-containing regimens, particularly in patients without actionable molecular alterations.

In recent years, the integration of precision oncology has significantly reshaped the treatment landscape for advanced BTC. Targeted therapies directed against FGFR2 fusions, IDH1 mutations, BRAF V600E mutations, NTRK fusions, HER2 amplifications, and microsatellite instability (MSI-H) have enabled more personalized treatment approaches. These advances have been particularly impactful in intrahepatic cholangiocarcinoma, where the prevalence of actionable genomic alterations is higher, marking a shift from empiric chemotherapy toward biomarker-driven treatment paradigms for selected patient populations.

Novel agents such as pemigatinib and zanidatamab, along with investigational therapies including rilvegostomig, lenvatinib mesylate, and other HER2- and immunotherapy-based combinations, are expanding precision oncology approaches in BTC. This transition marks a shift from chemotherapy-dominated management toward a more personalized and innovation-driven market focused on improving survival outcomes in genomically defined patient populations.

• The APAC BTC market is witnessing strong growth driven by the rising incidence of cholangiocarcinoma and gallbladder cancer, increasing adoption of molecular diagnostics, and expanding use of targeted therapies and immunotherapies.
• China currently dominates the regional market, while India and South Korea are emerging as high-growth markets due to improving oncology infrastructure and precision medicine adoption.
• Recent regulatory approvals have expanded targeted treatment options for BTCs. FGFR inhibitors, such as pemigatinib, are approved for FGFR2-fusion-positive cholangiocarcinoma, while IDH1 inhibitors, ivosidenib, are approved for IDH1-mutated disease following prior therapy.
• Durvalumab, a PD-L1 inhibitor, in combination with gemcitabine and platinum chemotherapy, is also established as a first-line immunochemotherapy option for advanced BTC in key regulatory regions.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Biliary Tract Cancer (BTC) (2022-2036 Forecast)

The BTC market comprises bispecific antibodies designed to address key oncogenic pathways such as FGFR2 alterations, HER2 overexpression, and immune checkpoint signaling in cholangiocarcinoma and other BTCs.

• Bispecific antibodies: Bispecific and next-generation antibody therapies are emerging as key innovations in BTC. zanidatamab, a HER2-targeted bispecific antibody, has demonstrated promising efficacy in HER2-positive BTC, while emerging candidates such as rilvegostomig are being developed to enhance anti-tumor immune responses through dual-targeting immunotherapy approaches.

Biliary Tract Cancer (BTC) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the BTC drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved Therapies in Biliary Tract Cancer (BTC)

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report....

Biliary Tract Cancer (BTC) Therapies Price Scenario & Trends

Pricing and analogue assessment of BTC therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and the understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Biliary Tract Cancer (BTC)

To keep up with BTC market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the BTC emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in BTC, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 15+ KOLs to gather insights at the country level. Centers such as the Chinese Academy of Medical Sciences & Peking Union Medical College, Third Military Medical University (Army Medical University), Datar Cancer Genetics, and the University of Melbourne, etc., were contacted. Their opinion helps understand and validate current and emerging BTC therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in BTC.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of BTC, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of BTC, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the BTC market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the APAC market drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the APAC BTC market.

Report Insights

• Biliary Tract Cancer (BTC) Patient Population Forecast
• Biliary Tract Cancer (BTC) Therapeutics Market Size
• Biliary Tract Cancer (BTC) Pipeline Analysis
• Biliary Tract Cancer (BTC) Market Size And Trends
• Biliary Tract Cancer (BTC) Market Opportunity (current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year forecast
• Biliary Tract Cancer (BTC) Market Outlook (Asia-Pacific)
• Patient Burden Trends (By Geography)
• Biliary Tract Cancer (BTC) Treatment Addressable Market (TAM)
• Biliary Tract Cancer (BTC) Competitive Landscape
• Biliary Tract Cancer (BTC) Major Companies Insights
• Biliary Tract Cancer (BTC) Price Trends and Analogue Assessment
• Biliary Tract Cancer (BTC) Therapies and Drug Adoption/Uptake
• Biliary Tract Cancer (BTC) Therapies Peak Patient Share Analysis

Report Assessment

• Biliary Tract Cancer (BTC) Current Treatment Practices
• Biliary Tract Cancer (BTC) Unmet Needs
• Biliary Tract Cancer (BTC) Clinical Development Analysis
• Biliary Tract Cancer (BTC) Emerging Drugs Product Profiles
• Biliary Tract Cancer (BTC) Market Attractiveness
• Biliary Tract Cancer (BTC) Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the Biliary Tract Cancer (BTC) market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of BTC?
• What are the disease risks, burdens, and unmet needs of BTC? What will be the growth opportunities across the APAC market concerning the patient population with BTC?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of BTC? What are the current guidelines for treating BTC in the APAC region?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the BTC market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarizes and simplifies complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.